In autoimmune diseases, the Slc7a5-mTORC1 pathway may offer a new therapeutic approach, LAT1 deletion or inhibition effectively regulates IL-23 and IL-1β-induced PI3K/AKT/mTOR activation [57]. Here, MTOR is linked to autoimmune disease.